Which aspects of HTS are empirically correlated with downstream success?

Curr Opin Drug Discov Devel 2008 May;11(3):327-37

Lead Finding Platform, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.

High-throughput screening (HTS) is a well-established hit-finding approach used in the pharmaceutical industry. In this article, recent experience at Novartis with respect to factors influencing the success of HTS campaigns is discussed. An inherent measure of HTS quality could be defined by the assay Z and Z' factors, the number of hits and their biological potencies; however, such measures of quality do not always correlate with the advancement of hits to the later stages of drug discovery. Also, for many target classes, such as kinases, it is easy to identify hits, but, as a result of selectivity, intellectual property and other issues, the projects do not result in lead declarations. In this article, HTS success is defined as the fraction of HTS campaigns that advance into the later stages of drug discovery, and the major influencing factors are examined. Interestingly, screening compounds in individual wells or in mixtures did not have a major impact on the HTS success and, equally interesting, there was no difference in the progression rates of biochemical and cell-based assays. Particular target types, assay technologies, structure-activity relationships and powder availability had a much greater impact on success as defined above. In addition, significant mutual dependencies can be observed - while one assay format works well with one target type, this situation might be completely reversed for a combination of the same readout technology with a different target type. The results and opinions presented here should be regarded as groundwork, and a plethora of factors that influence the fate of a project, such as biophysical measurements, chemical attractiveness of the hits, strategic reasons and safety pharmacology, are not covered here. Nonetheless, it is hoped that this information will be used industry-wide to improve success rates in terms of hits progressing into exploratory chemistry and beyond. The support that can be obtained from new in silico approaches to phase transitions are also described, along with the gaps they are designed to fill.

Download full-text PDF

Source
May 2008

Similar Publications

Novel trends in high-throughput screening.

Curr Opin Pharmacol 2009 Oct 21;9(5):580-8. Epub 2009 Sep 21.

Novartis Institutes for BioMedical Research, Center of Proteomic Chemistry, Protease Platform, Novartis Campus, CH-4002 Basel, Switzerland.

High-throughput screening (HTS) is a well-established process for lead discovery in Pharma and Biotech companies and is now also being used for basic and applied research in academia. It comprises the screening of large chemical libraries for activity against biological targets via the use of automation, miniaturized assays and large-scale data analysis. Since its first advent in the early to mid 1990s, the field of HTS has seen not only a continuous change in technology and processes, but also an adaptation to various needs in lead discovery. Read More

View Article and Full-Text PDF
October 2009

Affinity-based screening techniques for enhancing lead discovery.

Curr Opin Drug Discov Devel 2004 Jul;7(4):411-6

Abbott Laboratories, Global Pharmaceutical Research Division, 100 Abbott Park Road, Abbott Park, IL 60048, USA.

Contemporary, rational small-molecule lead discovery methods, comprising target identification, assay development, high-throughput screening (HTS), hit characterization and medicinal chemistry optimization, dominate early-stage drug discovery strategies in many pharmaceutical companies. There is a growing disparity between the increasing cost of funding these methods and the decreasing number of new drugs reaching the market. New strategies must be adopted to reverse this trend. Read More

View Article and Full-Text PDF
July 2004

Chemical feature-based pharmacophores and virtual library screening for discovery of new leads.

Curr Opin Drug Discov Devel 2003 May;6(3):370-6

Leopold-Franzens University of Innsbruck, Institute of Pharmacy, Computer Aided Molecular Design Group, Innrain 52, A-6020 Innsbruck, Austria.

During the past years, efforts in the pharmaceutical industry have focused on optimizing the early phase hit-to-lead development of the drug discovery process. In silico-based high-throughput screening (HTS) approaches emerged, with a number of issues arising, such as the need for efficient search algorithms, library design, diversity, drug- and/or lead-likeness. These problems were addressed in numerous publications. Read More

View Article and Full-Text PDF
May 2003

The impact of diversity-based, high-throughput screening on drug discovery: "chance favours the prepared mind".

Curr Opin Drug Discov Devel 2008 Jul;11(4):553-8

GlaxoSmithKline Research & Development Ltd, New Frontiers Science Park, Third Avenue, Harlow, Essex, CM19 5AW, UK.

Since its modest beginnings in support of natural product discovery in the early 1980s, diversity-based high-throughput screening (dHTS) has developed within the pharmaceutical, biotechnology and academic sectors to become one of the most widely used hit identification screening paradigms in early drug discovery. Advances in key component technologies, specifically in diversity collection design, high-throughput assay development and screening informatics, continue to improve the economics and successes of dHTS hit discovery from large screening collections. Through the application of these components in concert, dHTS has evolved from an expensive technology-centric process that was used to screen collections of randomly acquired compounds, into a process that balances chemical, biological and technological inputs to purposefully build diverse compound collections through planned synthesis and purchasing strategies, and that screens these collections efficiently and economically. Read More

View Article and Full-Text PDF
July 2008